Marta Hamilton - Concepedia

Author

Marta Hamilton

Gilead Sciences (United States)

Also Known As

M HAMILTON, M Hamilton, M. Hamilton, M. M. Hamilton, M.M. Hamilton, Marta Hamilton

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Gilead Sciences (United States)La Roche College University of Arizona Eli Lilly (United States)The University of Texas Health Science Center at San Antonio

About

Marta Hamilton is an author at Gilead Sciences (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	21	1.1K
2	Health Sciences	2	2	296
3	Education	1	1	33
4	Public Health	1	1	17
5	Behavioral Health	1	1	267

Marta Hamilton

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Effects of Smoking on the Pharmacokinetics of Erlotinib Marta Hamilton, Julie Wolf, Jason Rusk, Clinical Cancer Research	2006	308
Results of a Randomized Controlled Trial of Mental Illness Self-management Using Wellness Recovery Action Planning Judith Α. Cook, Mary Ellen Copeland, Jessica A. Jonikas, Schizophrenia Bulletin PsychotherapyUsual CareMental Health InterventionMental HealthSelf-care Intervention	2011	267
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma Sith Sathornsumetee, Annick Desjardins, James J. Vredenburgh, Neuro-Oncology	2010	226
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non–small cell lung cancer Jianfeng Lü, Steve Eppler, J WOLF, Clinical Pharmacology & Therapeutics	2006	223
METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS Jie Ling, Kim A. Johnson, Zhuang Miao, Drug Metabolism and Disposition	2005	219
Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus Macaques Koen K. A. Van Rompay, Laurie Brignolo, Dennis J. Meyer, Antimicrobial Agents and Chemotherapy	2004	141
Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study Regina I. Jakacki, Marta Hamilton, Richard J. Gilbertson, Journal of Clinical Oncology	2008	130
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition Ashok Rakhit, Michael Pantze, Scott Fettner, European Journal of Clinical Pharmacology Pharmacokinetic ModelingCyp3a4 InhibitionErlotinib PharmacokineticsMedicineVivo Metabolic Inhibition	2007	120
Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects Paul Frohna, Jianfeng Lu, Steve Eppler, The Journal of Clinical Pharmacology Oral BioavailabilityHealthy SubjectsPharmacological StudyMedicineReceptor Tyrosine Kinase	2006	109
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers W. Jeffrey Petty, Konstantin H. Dragnev, Vincent A. Memoli, Clinical Cancer Research	2004	95

Page 1